Trial Profile

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
Focus Registrational; Therapeutic Use
Acronyms DUO-O
Sponsors AstraZeneca; AstraZeneca AB; Myriad Genetic Laboratories

25 Jul 2024 Planned End Date changed from 25 May 2028 to 30 Mar 2028.
25 Jul 2024 Planned primary completion date changed from 28 Aug 2023 to 28 Mar 2025.
24 Aug 2023 Planned primary completion date changed from 23 Jun 2023 to 28 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com